Analyst firms · Morgan Stanley · GMAB
Morgan Stanley GMAB price target and rating history
Genmab A/S (GMAB) · Health Care
Morgan Stanley rates Genmab A/S (GMAB) Equal-Weight with a $34 price target, as of its latest action on Feb 17, 2026. It has published 4 rating actions on GMAB since September 2021, including 0 upgrades and 1 downgrade. Across 6 firms with a GMAB price target in the last 12 months, the median target is $40. Morgan Stanley's $34 is 15% below that.
- Current rating
- Equal-Weight
- Price target
- $34
- Median target, all firms
- $40
- Actions on GMAB
- 4
Morgan Stanley price target on GMAB
Every Morgan Stanley rating on GMAB
- Feb 17, 2026
- Sep 4, 2024
- May 12, 2023
- Sep 7, 2021
How other firms rate GMAB
Each firm's latest rating and stated target in the last 12 months.
| Firm | Rating | Price target | Date |
|---|---|---|---|
| TD Cowen | Buy | $43 | Jul 22, 2026 |
| Truist Securities | Buy | $40 | May 27, 2026 |
| Goldman Sachs | Buy | Apr 22, 2026 | |
| Wolfe Research | Outperform | $32 | Mar 27, 2026 |
| Wells Fargo | Overweight | $40 | Mar 2, 2026 |
| Jefferies | Buy | $41.50 | Feb 17, 2026 |
| Morgan Stanley | Equal-Weight | $34 | Feb 17, 2026 |
Questions about Morgan Stanley and GMAB
- What is Morgan Stanley's price target for GMAB?
- Morgan Stanley's latest stated price target for Genmab A/S (GMAB) is $34, from its action on Feb 17, 2026.
- What is Morgan Stanley's rating on GMAB?
- Morgan Stanley rates GMAB Equal-Weight, a neutral rating, as of Feb 17, 2026.
- When did Morgan Stanley last change its view on GMAB?
- On Feb 17, 2026, Morgan Stanley resumes coverage at Equal-Weight, price target $34.
- How does Morgan Stanley's GMAB target compare with other analysts?
- Across 6 firms with a GMAB price target in the last 12 months, the median target is $40. Morgan Stanley's $34 is 15% below that.
More GMAB rating histories
All Morgan Stanley ratingsGMAB news and filingsEvery analyst firm
From rating actions in the Quantisnow feed. A target holds until the firm states a new one; a reiteration with no target keeps the last one. Not investment advice.